María Pilar
Garrido López

Profesor/a Asociado/a en CC. de la Salud

Foto de María Pilar

Foto de Eli Lilly and Company

Eli Lilly and Company

Indianapolis, EE. UU.

Eli Lilly and Company-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2021

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Clinical Cancer Research, Vol. 27, Núm. 4, pp. 992-1003

2020

Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer
Lung Cancer, Vol. 142, pp. 63-69

2018

Abemaciclib in combination with single-agent options in patients with stage IV non–small cell lung cancer: A phase Ib study
Clinical Cancer Research, Vol. 24, Núm. 22, pp. 5543-5551

2017

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: Results by age subgroup
ESMO Open

2015

Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC)
Lung Cancer, Vol. 88, Núm. 2, pp. 160-166